# A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

> **NCT02316353** · PHASE3 · COMPLETED · sponsor: **CSL Behring** · enrollment: 126 (actual)

## Conditions studied

- Hereditary Angioedema Types I and II

## Interventions

- **BIOLOGICAL:** C1-esterase inhibitor

## Key facts

- **NCT ID:** NCT02316353
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-31
- **Primary completion:** 2017-09-21
- **Final completion:** 2017-09-21
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02316353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02316353, "A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT02316353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*